Onco-Innovations (FRA:W1H) DeferredTaxAndRevenue: €0.00 Mil (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:W1H Onco-Innovations Ltd FRA:W1H
20 GF Score
Price €0.34
! 2 Warning Signs
View Full Analysis

What is Onco-Innovations DeferredTaxAndRevenue?

Onco-Innovations FRA:W1H -0.73% 20 DeferredTaxAndRevenue is €0.00 Mil as of Apr. 2026. GuruFocus rates FRA:W1H with a GF Score™ of 20/100. The stock has 2 warning signs investors should review.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Onco-Innovations's current deferred tax and revenue for the quarter that ended in Apr. 2026 was €0.00 Mil.

Onco-Innovations DeferredTaxAndRevenue Related Terms

Onco-Innovations DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for Onco-Innovations's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Onco-Innovations DeferredTaxAndRevenue Chart

Onco-Innovations Annual Data
Trend Apr23 Apr24 Apr25 Apr26
DeferredTaxAndRevenue
0.00 0.00 0.00 0.00

Onco-Innovations Quarterly Data
Apr23 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:W1H
20GF Score
Onco-Innovations Ltd FRA:W1H
DeferredTaxAndRevenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of €0.00 Mil mean?
Onco-Innovations (FRA:W1H) has a DeferredTaxAndRevenue of €0.00 Mil as of Apr. 2026. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Onco-Innovations.
Is Onco-Innovations' DeferredTaxAndRevenue too high?
Onco-Innovations' current DeferredTaxAndRevenue is €0.00 Mil. Overall, Onco-Innovations has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Onco-Innovations' DeferredTaxAndRevenue compare to VRTX and REGN?
Onco-Innovations' DeferredTaxAndRevenue of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Biotechnology company?
A good DeferredTaxAndRevenue depends on the Biotechnology industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Onco-Innovations. Onco-Innovations's current DeferredTaxAndRevenue is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Onco-Innovations stock overvalued right now?
Onco-Innovations (FRA:W1H) has a current DeferredTaxAndRevenue of €0.00 Mil. The current DeferredTaxAndRevenue is €0.00 Mil. Onco-Innovations' overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For Onco-Innovations (FRA:W1H), the current DeferredTaxAndRevenue is €0.00 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Onco-Innovations Business Description

Other Exchanges W1H:GermanyONCO:Canada
Address 7th Street South West, Suite 1039, Calgary, AB, CAN, T2R 1A5
Onco-Innovations Ltd is a pre-clinical stage biotechnology company working on developing drug candidates that can increase the effectiveness of current cancer treatments.
20GF Score

Get the complete analysis for FRA:W1H

DeferredTaxAndRevenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.34
Price